Lead Product(s) : Rosiglitazone
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rosiglitazone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2011
Lead Product(s) : Rosiglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rosiglitazone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
Details : Rosiglitazone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2011
Lead Product(s) : Rosiglitazone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rosiglitazone
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
Details : Rosiglitazone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Metabolic Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2010
Lead Product(s) : Rosiglitazone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rosiglitazone
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rosiglitazone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thyroid Cancer, Papillary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 09, 2010
Lead Product(s) : Rosiglitazone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
